Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

The company plans to use some of the funds to support development of a kinase inhibitor in Phase I testing for BCR-ABL fusion-positive chronic myeloid leukemia.

NEW YORK – Syndax Pharmaceuticals unveiled new data this week from the Phase I/II AUGMENT-101 trial of its menin inhibitor Revuforj (revumenib) in patients with relapsed or refractory NPM1-mutated ...

The agency approved a perioperative Keytruda regimen based on a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

The biotech, known as the developer of the first CRISPR drug, will consolidate sites in the state as it stops developing a diabetes cell therapy.

NEW YORK – Ionis Pharmaceuticals has treated the first patient in a Phase III clinical trial evaluating the efficacy and safety of its investigational antisense oligonucleotide (ASO) therapy for ...

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.